Table 2 Clinical features and outcomes of patients with breakthrough bloodstream infection (BSI) during tigecycline therapy.
Variable | No (%) of patients |
|---|---|
Source of breakthrough BSI | |
Intraabdominal infection | 39 (33.9) |
Hepatobiliary infection | 22 (19.1) |
Catheter-related infection | 35 (30.4) |
Primary BSI | 7 (6.1) |
Skin and soft tissue infection | 6 (5.2) |
Respiratory tract infection | 3 (2.6) |
Urinary tract infection | 3 (2.6) |
Length of tigecycline therapy before BSI (day), median (IQR) | 8.0 (4–13.5) |
Pitt bacteremia score, median (IQR) | 2 (1–5) |
Sepsis grade | |
Without SIRS | 5 (4.3) |
Sepsis | 37 (32.2) |
Severe sepsis | 42 (36.5) |
Septic shock | 31 (27.0) |
ICU care after BSI | 72 (62.6) |
Outcome | |
7-day mortality | 9 (7.8) |
30-day mortality | 25 (21.7) |
In-hospital mortality | 49 (42.6) |
Time to death (day), median (IQR) | 33 (14–89.5) |
